The benefits and risks of pembrolizumab in combination with chemotherapy as first-line therapy in small-cell lung cancer: a single-arm meta-analysis of noncomparative clinical studies and randomized…

Overview of attention for article published in World Journal of Surgical Oncology, October 2021

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (59th percentile)
High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

twitter: 7 X users

Citations

dimensions_citation: 5 Dimensions

Readers on

mendeley: 40 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 7 X posts from 7 X users, with an upper bound of 41,203 followers.

The benefits and risks of pembrolizumab in combination with chemotherapy as first-line therapy in small-cell lung ... https://t.co/kRUjptCaky

12 Dec 2021

Reply Repost Favourite

The benefits and risks of pembrolizumab in combination with chemotherapy as first-line therapy in small-cell lung cancer: a single-arm meta-analysis of noncomparative clinical studies and randomized control trials | World Journal of Surgical Oncology | htt

22 Oct 2021

Reply Repost Favourite

RT @Dr_Ivanoncologo: ➡️This #study was performed to discern the efficacy and risk of #pembrolizumab in combination with #chemotherapy as fi…

19 Oct 2021

Reply Repost Favourite

RT @Dr_Ivanoncologo: ➡️This #study was performed to discern the efficacy and risk of #pembrolizumab in combination with #chemotherapy as fi…

19 Oct 2021

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 3 additional X posts.